Abbott Laboratories (ABT) Research & Development (2009 - 2026)

Abbott Laboratories has disclosed Research & Development across 18 years of filings, most recently posting $767.0 million for Q1 2026.

• Research & Development for Q1 2026 came in at $767.0 million, up 7.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.0 billion (up 4.07% YoY), and the FY2025 annual result was $2.9 billion, up 3.45% from the prior year.
• Research & Development came in at $767.0 million for Q1 2026 at Abbott Laboratories, up from $735.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $782.0 million in Q3 2022 to a low of $654.0 million in Q1 2023.
• The 5-year median for Research & Development is $715.0 million (2023), against an average of $716.6 million.
• Across the five-year window, Research & Development grew 16.37% in 2022 and dropped 14.07% in 2023, its largest moves.
• Abbott Laboratories' Research & Development stood at $725.0 million in 2022, then retreated by 3.45% to $700.0 million in 2023, then rose by 7.0% to $749.0 million in 2024, then retreated by 1.87% to $735.0 million in 2025, then advanced by 4.35% to $767.0 million in 2026.
• The last three Research & Development figures came in at $767.0 million (Q1 2026), $735.0 million (Q4 2025), and $766.0 million (Q3 2025), per Business Quant data.